摘要
目的 探讨安罗替尼联合顺铂治疗非小细胞肺癌患者的临床疗效。方法 根据治疗方式的不同将100例非小细胞肺癌患者分为对照组和观察组,每组50例,对照组患者采取顺铂治疗,观察组患者采取安罗替尼联合顺铂治疗。比较两组患者的临床疗效、血清肿瘤标志物[癌胚抗原(CEA)、糖类抗原125(CA125)、神经元特异性烯醇化酶(NSE)]水平、转化生长因子-β1(TGF-β1)水平、基质金属蛋白酶2(MMP2)水平及不良反应发生情况。结果 观察组患者的总有效率为90.00%,高于对照组患者的70.00%,差异有统计学意义(P﹤0.05)。治疗后,两组患者的血清CEA、CA125、NSE、TGF-β1、MMP2水平均低于本组治疗前,观察组患者的血清CEA、CA125、NSE、TGF-β1、MMP2水平均低于对照组,差异均有统计学意义(P﹤0.05)。两组患者红细胞减少、高血压、白细胞减少、腹泻、恶心呕吐、中性粒细胞减少发生率比较,差异均无统计学意义(P﹥0.05)。结论 安罗替尼联合顺铂治疗非小细胞肺癌患者可提高临床疗效,降低血清肿瘤标志物水平及TGF-β1、MMP2水平,且未增加不良反应。
Objective To investigate the clinical efficacy of anlotinib combined with cisplatin in the treatment of pa-tients with non-small cell lung cancer.Method A total of 100 patients with non-small cell lung cancer were divided into control group and observation group according to different treatment methods,with 50 cases in each group.The patients in the control group were treated with cisplatin,and the patients in the observation group were treated with anlotinib com-bined with cisplatin.The clinical efficacy,serum tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),neuron specific enolase(NSE)]levels,transforming growth factor-β1(TGF-β1)level,matrix metallopro-teinase 2(MMP2)level,and adverse events were compared between the two groups.Result The total effective rate of the observation group was 90.00%,which was higher than 70.00%of the control group,and the difference was statistical-ly significant(P<0.05).After the treatment,the serum levels of CEA,CA125,NSE,TGF-β1,and MMP2 in the two groups were lower than those before the treatment,and the serum levels of CEA,CA125,NSE,TGF-β1,and MMP2 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There were no significant differences in the incidence rate of erythropenia,hypertension,leukopenia,diarrhea,nau-sea and vomiting,and neutropenia between the two groups(P>0.05).Conclusion Anlotinib combined with cisplatin in the treatment of patients with non-small cell lung cancer could improve clinical efficacy,and reduce serum tumor marker levels and TGF-β1,MMP2 levels,without increasing the risk of adverse events.
作者
朱海霞
汪旅州
李少良
柯贤胜
ZHU Haixia;WANG Lyuzhou;LI Shaoliang;KE Xiansheng(Department of Oncology,Wuxue No.1 People’s Hospital,Huanggang 435400,Hubei,China)
出处
《癌症进展》
2023年第12期1365-1368,共4页
Oncology Progress
关键词
非小细胞肺癌
安罗替尼
顺铂
临床疗效
non-small cell lung cancer
anlotinib
cisplatin
clinical efficacy
